In the last trading session, 15.44 million Passage Bio Inc (NASDAQ:PASG) shares changed hands as the company’s beta touched 1.22. With the company’s per share price at $1.13 changed hands at $0.46 or 69.52% during last session, the market valuation stood at $118.32M. PASG’s last price was a discount, traded about -58.41% off its 52-week high of $1.79. The share price had its 52-week low at $0.45, which suggests the last value was 60.18% up since then. When we look at Passage Bio Inc’s average trading volume, we note the 10-day average is 1.97 million shares, with the 3-month average coming to 513.09K.
Analysts gave the Passage Bio Inc (PASG) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended PASG as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight.
Passage Bio Inc (NASDAQ:PASG) trade information
Instantly PASG was in green as seen at the end of in last trading. With action 110.82%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 11.88%, with the 5-day performance at 110.82% in the green. However, in the 30-day time frame, Passage Bio Inc (NASDAQ:PASG) is 81.21% up. Looking at the short shares, we see there were 1.64 million shares sold at short interest cover period of 6.61 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 81.17% from its current market value. According to analyst projections, PASG’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -430.97% plunge from its current level, while the stock would need to soar -430.97% for it to hit the projected low.
Passage Bio Inc (PASG) estimates and forecasts
Data shows that the Passage Bio Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -0.88% over the past 6 months, a 43.01% in annual growth rate that is considerably higher than the industry average of 17.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -46.23%. The 2024 estimates are for Passage Bio Inc earnings to increase by 42.26%.
PASG Dividends
Passage Bio Inc is expected to release its next quarterly earnings report in January.
Passage Bio Inc (NASDAQ:PASG)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.49% of Passage Bio Inc shares while 59.68% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 59.98%. There are 59.68% institutions holding the Passage Bio Inc stock share, with ORBIMED ADVISORS LLC the top institutional holder. As of 2024-06-30, the company held 17.9847% of the shares, roughly 10.12 million PASG shares worth $8.04 million.
VESTAL POINT CAPITAL, LP holds the second largest percentage of outstanding shares, with 10.7504% or 6.05 million shares worth $4.81 million as of 2024-06-30.
